RAFAEL HOLDINGS, INC. Proceeds from Sale and Maturity of Marketable Securities
RAFAEL HOLDINGS, INC. (RFL) reported Proceeds from Sale and Maturity of Marketable Securities of $271.00 thousand for the 6-month period ending 2024-01-31, per its 10-Q filed 2024-03-14.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2024-03-14
- RAFAEL HOLDINGS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2024-01-31 was $0.00.
- RAFAEL HOLDINGS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2023-10-31 was $271.00K, a 99.45% decline year-over-year.
- RAFAEL HOLDINGS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2023-07-31 was -$48.08M.
- RAFAEL HOLDINGS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2023-04-30 was $0.00.
- RAFAEL HOLDINGS, INC. proceeds from sale and maturity of marketable securities for fiscal 2023 was $1.32M.
- RAFAEL HOLDINGS, INC. proceeds from sale and maturity of marketable securities for fiscal 2021 was $7.00M.
- RAFAEL HOLDINGS, INC. proceeds from sale and maturity of marketable securities for fiscal 2019 was $25.03M, a 275.28% increase from fiscal 2018.
- RAFAEL HOLDINGS, INC. proceeds from sale and maturity of marketable securities for fiscal 2018 was $6.67M.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2024-01-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-03-14 | $271.00K 10-Q · filed 2024-03-14 | -$47.80M derived: sum of 3 quarters · filed 2024-03-14 | -$47.80M derived: sum of 4 quarters · filed 2024-03-14 |
| 2023-10-31 | $271.00K 10-Q · filed 2023-12-14 | -$47.80M derived: sum of 2 quarters · filed 2023-12-14 | -$47.80M derived: sum of 3 quarters · filed 2023-12-14 | -$47.80M derived: sum of 4 quarters · filed 2023-12-14 |
| 2023-07-31 | -$48.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-30 | -$48.08M derived: sum of 2 quarters · filed 2023-10-30 | -$48.08M derived: sum of 3 quarters · filed 2023-10-30 | $1.32M 10-K · filed 2023-10-30 |
| 2023-04-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-06-13 | $0.00 derived: sum of 2 quarters · filed 2023-06-13 | $49.40M 10-Q · filed 2023-06-13 | |
| 2023-01-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-03-14 | $49.40M 10-Q · filed 2023-03-14 | ||
| 2022-10-31 | $49.40M 10-Q · filed 2022-12-13 | |||
| 2021-07-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-10-31 | $5.00M derived: sum of 2 quarters · filed 2022-10-31 | $5.00M derived: sum of 3 quarters · filed 2022-10-31 | $7.00M 10-K · filed 2022-10-31 |
| 2021-04-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-06-14 | $0.00 derived: sum of 2 quarters · filed 2022-06-14 | $2.00M 10-Q · filed 2022-06-14 | |
| 2021-01-31 | $0.00 derived: 10-Q 6 month − 10-Q/A 3 month · filed 2022-03-17 | $2.00M 10-Q · filed 2022-03-17 | ||
| 2020-10-31 | $2.00M 10-Q/A · filed 2022-02-28 | |||
| 2019-07-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-29 | $0.00 derived: sum of 2 quarters · filed 2020-10-29 | $19.21M derived: sum of 3 quarters · filed 2020-10-29 | $25.03M 10-K · filed 2020-10-29 |
| 2019-04-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-06-09 | $19.21M derived: sum of 2 quarters · filed 2020-06-09 | $25.03M 10-Q · filed 2020-06-09 | $31.27M derived: sum of 4 quarters · filed 2020-06-09 |
| 2019-01-31 | $19.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-03-05 | $25.03M 10-Q · filed 2020-03-05 | $31.27M derived: sum of 3 quarters · filed 2020-03-05 | |
| 2018-10-31 | $5.82M 10-Q · filed 2019-12-09 | $12.05M derived: sum of 2 quarters · filed 2019-12-09 | ||
| 2018-07-31 | $6.23M derived: 10-K 12 month − 10-Q 9 month · filed 2019-10-04 | $6.67M 10-K · filed 2019-10-04 | ||
| 2018-04-30 | $436.00K 10-Q · filed 2019-06-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |